Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, December 16, 2024; Inify Laboratories AB (publ.) announces that the below primary insider was allocated new shares at the Offer Price in the Private Placement as further specified in the attached notification forms: -          Gallivant S.à r.l. and Monsun AS, companies closely associated with board member Magne Jordanger, have been allocated 20,229,274 and 5,022,570 Private Placement Shares, respectively (in aggregate: 25,251,844 Private Placement Shares). Gallivant S.à r.l. and Monsun AS will, subject to completion of the Private Placement own 47,410,660 and 6,009,520 shares, respectively, in the Company. For further information, please contact CEO, Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com. This information is subject to the disclosure requirements in the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act. ### About Inify Laboratories Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer's organization. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.